The latest price target for Syros Pharmaceuticals (NASDAQ:SYRS) was reported by JMP Securities on August 13, 2024. The analyst firm set a price target for $4.00 expecting SYRS to rise to within 12 months (a possible 159.74% upside). 9 analyst firms have reported ratings in the last year.

The latest analyst rating for Syros Pharmaceuticals (NASDAQ:SYRS) was provided by JMP Securities, and Syros Pharmaceuticals maintained their market outperform rating.

There is no last upgrade for Syros Pharmaceuticals

There is no last downgrade for Syros Pharmaceuticals.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Syros Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Syros Pharmaceuticals was filed on August 13, 2024 so you should expect the next rating to be made available sometime around August 13, 2025.

While ratings are subjective and will change, the latest Syros Pharmaceuticals (SYRS) rating was a maintained with a price target of $12.00 to $4.00. The current price Syros Pharmaceuticals (SYRS) is trading at is $1.54, which is out of the analyst’s predicted range.